PLK1 and non-small cell lung carcinoma: This selective, small-molecule, dihydropteridinone-derived, adenosine triphosphate-competitive kinase inhibitor of Plks 1–3 showed promise in preclinical experiments, validating Plks as potential drug targets in oncology.7,11 Unfortunately, phase II trials in patients with relapsed/refractory solid tumors,12 non-small-cell lung cancer (NSCLC),13 small-cell lung cancer,14 chemotherapy-naive pancreatic cancer15 and relapsed/refractory AML16 demonstrated that BI 2536 had modest, if any, clinical activity and was associated with a generally manageable safety profile.